AI Article Synopsis
- Boron neutron capture therapy (BNCT) uses specialized boron-10 compounds for treating tumors, specifically through a new boron-10 derivative called ACBC-BSH that targets glioma cells.
- In vitro studies showed that ACBC-BSH had better uptake in glioma cells compared to other compounds, and in vivo studies indicated it achieved higher tumor boron concentrations than the standard boronophenylalanine (BPA) treatment.
- The survival of rats treated with BNCT using ACBC-BSH/CED was extended compared to those treated with BPA/i.v., highlighting the potential effectiveness of this new therapy in glioma treatment.
Article Abstract
Background: Boron neutron capture therapy (BNCT) is a unique particle radiation therapy based on the nuclear capture reactions in boron-10. We developed a novel boron-10 containing sodium borocaptate (BSH) derivative, 1-amino-3-fluorocyclobutane-1-carboxylic acid (ACBC)-BSH. ACBC is a tumor selective synthetic amino acid. The purpose of this study was to assess the biodistribution of ACBC-BSH and its therapeutic efficacy following Boron Neutron Capture Therapy (BNCT) of the F98 rat glioma.
Methods: We evaluated the biodistribution of three boron-10 compounds, ACBC-BSH, BSH and boronophenylalanine (BPA), in vitro and in vivo, following intravenous (i.v.) administration and intratumoral (i.t.) convection-enhanced delivery (CED) in F98 rat glioma bearing rats. For BNCT studies, rats were stratified into five groups: untreated controls, neutron-irradiation controls, BNCT with BPA/i.v., BNCT with ACBC-BSH/CED, and BNCT concomitantly using BPA/i.v. and ACBC-BSH/CED.
Results: In vitro, ACBC-BSH attained higher cellular uptake F98 rat glioma cells compared with BSH. In vivo biodistribution studies following i.v. administration and i.t. CED of ACBC-BSH attained significantly higher boron concentrations than that of BSH, but much lower than that of BPA. However, following convection enhanced delivery (CED), ACBC-BSH attained significantly higher tumor concentrations than BPA. The i.t. boron-10 concentrations were almost equal between the ACBC-BSH/CED group and BPA/i.v. group of rats. The tumor/brain boron-10 concentration ratio was higher with ACBC-BSH/CED than that of BPA/i.v. group. Based on these data, BNCT studies were carried out in F98 glioma bearing rats using BPA/i.v. and ACBC-BSH/CED as the delivery agents. The corresponding mean survival times were 37.4 ± 2.6d and 44.3 ± 8.0d, respectively, and although modest, these differences were statistically significant.
Conclusions: Our findings suggest that further studies are warranted to evaluate ACBC-BSH/CED as a boron delivery agent.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260095 | PMC |
| http://dx.doi.org/10.1186/s13014-017-0765-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CXCL12 impact on glioblastoma cells behaviors under dynamic culture conditions: Insights for developing new therapeutic approaches.
PLoS One
December 2024
Faculty of Engineering, Department of Chemical Engineering and Biotechnological Engineering, 3D Dynamic Cell Culture Systems Laboratory, Université de Sherbrooke, Sherbrooke, QC, Canada.
Glioblastoma multiforme (GBM) is the most prevalent malignant brain tumor, with an average survival time of 14 to 20 months. Its capacity to invade brain parenchyma leads to the failure of conventional treatments and subsequent tumor recurrence. Recent studies have explored new therapeutic strategies using a chemoattracting gradient to attract GBM cells into a soft hydrogel trap where they can be exposed to higher doses of radiation or chemotherapy.
View Article and Find Full Text PDFUltrasmall solid lipid nanoparticles as a potential innovative delivery system for a drug combination against glioma.
Nanomedicine (Lond)
January 2025
R Bio Transfer srl, Salerno, Italy.
Introduction: High grade gliomas are characterized by a very poor prognosis due to fatal relapses after surgery. Current chemotherapy is only a palliative care, while potential drug candidates are limited by poor overcoming of the blood-brain barrier.
Aims: A suitable chemotherapeutic approach should be engineered to overcome both the altered blood-brain barrier in the glioma site, as well as the intact one in the brain adjacent to tumor zone, and to target the multiple factors influencing glioma proliferation, differentiation, migration, and angiogenesis.
Increased Cellular Uptake of ApoE3- or c(RGD)-Modified Liposomes for Glioblastoma Therapy Depending on the Target Cells.
Pharmaceutics
August 2024
ABNOBA GmbH, 75223 Niefern-Öschelbronn, Germany.
As effective treatment of glioblastoma is still an unmet need, targeted delivery systems for efficient treatment are of utmost interest. Therefore, in this paper, surface modifications with a small peptide c(RGD) or physiological protein (ApoE3) were investigated. Cellular uptake in murine endothelial cells (bEnd.
View Article and Find Full Text PDFJiawei Bai-Hu-decoction ameliorated heat stroke-induced brain injury by inhibiting TLR4/NF-κB signal and mitophagy of glial cell.
J Ethnopharmacol
November 2024
Guangzhou Hospital of Integrated Traditional and Western Medicine Affiliated to Guangzhou University of Chinese Medicine, No.87 Yingbin Avenue, Huadu District, Guangzhou, 510801, PR China; School of Pharmaceutical Science, Guangzhou University of Chinese Medicine, No. 232, Waihuandong Road, Guangzhou, 510006, PR China; Guangzhou Huadu District Women and Children's Health Hospital, No.51, Jianshe Road, Huadu District, Guangzhou, 510800, PR China. Electronic address:
Ethnopharmacological Relevance: Jiawei Bai-Hu-Decoction (JWBHD), a prescription formulated with seven traditional Chinese medicinal material has demonstrated clinical efficacy in mitigating brain injury among heat stroke (HS) patients.
Aim Of The Study: This study aimed to evaluate the therapeutic efficacy of JWBHD on rat model of HS and to explore its therapeutic mechanisms by integrating network pharmacology and pharmacodynamic methodologies, which major components were analyzed by using UPLC-MS/MS.
Materials And Methods: The network pharmacology analysis was firstly conducted to predict the potential active ingredients and therapeutic targets of JWBHD.
A neural tract-inspired conduit for facile, on-demand biopsy of glioblastoma.
Neurooncol Adv
May 2024
Department of Neurosurgery, Emory University, Atlanta, Georgia, USA.
Article Synopsis
- The study addresses a key challenge in treating glioblastoma (GBM) by using a new device that offers continuous access to tumors, improving our understanding of tumor progression and treatment responses.
- Researchers tested an aligned nanofiber device in rodent models and found it to be safe, providing ample high-quality samples for genomic analyses and allowing for the study of tumor behavior over time.
- The findings suggest that this device could become a valuable tool for monitoring GBM and tailoring clinical treatments based on real-time data from the tumor environment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!